袁浩亮，博士，副研究员，博士生导师。2014年获中国药科大学药物化学博士学位。2015年加入中国药科大学药物科学研究院新药研究中心工作至今。主持国家自然科学基金面上项目3项、青年项目1项、重庆市自然科学基金面上项目1项，中央高校基本科研业务费项目1项，另参与多项国家和省部级科研项目。以第一作者/通讯作者在药物化学专业领域J. Med. Chem.，Eur. J. Med. Chem.，J. Chem. Inf. Model.等期刊发表SCI论文20余篇，申请国内/外专利多项。

研究方向：计算机辅助药物分子发现及新药研究

联系方式：yhl@cpu.edu.cn

通讯地址：江苏省南京市江宁区龙眠大道639号中国药科大学，邮编：211198

代表性论文：

(1)  Panpan Chen#, Cai Chen#, Yizheng Zheng, Fangjun Chen, Zhaojun Liu, Shenhong Ren, Hangyu Song, Tongdan Liu, Zhipeng Lu, Hongbin Sun*, Yi Kong*, and Haoliang Yuan*, Discovery of 2, 3-dihydro-[1,4]dioxino[2,3-g]benzofuran Derivatives as Protease Activated Receptor 4 (PAR4) Antagonists with Potent Antiplatelet Aggregation Activity And Low Bleeding Tendency, J. Med. Chem. 2024, doi: 10.1021/acs.jmedchem.3c02099.

(2)  Liu Liu#, Honghan Zhang#, Jie Hou#, Yuying Zhang#, Luosen Wang, Shijun Wang, Zhiying Yao, Tao Xie, Xiaoan Wen, Qinglong Xu, Liang Dai, Zhiqi Feng, Pu Zhang, Yaojun Wu, Hongbin Sun*, Jun Liu*, Haoliang Yuan*. Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity, J. Med. Chem. 2024, 67:4977-4997.

(3)  Hengzhi Sun#, Jinzheng Wang#, Shengjie Liu#, Xinyu Zhou#, Liang Dai, Caiping Chen, Qinglong Xu, Xiaoan Wen, Keguang Cheng, Hongbin Sun*, Haoliang Yuan*, Discovery of Novel Small Molecule Inhibitors Disrupting the PCSK9-LDLR Interaction. J. Chem. Inf. Model. 2021, 61, 5269-5279. 

(4)  Liu Liu#, Zhiying Yao#, Shijun Wang#, Tao Xie, Guoqing Wu, Honghan Zhang, Pu Zhang, Yaojun Wu, Haoliang Yuan*, Hongbin Sun*. Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[C][1,2,5]Oxadiazole Derivatives as Potent Pd-L1 Inhibitors with in Vivo Antitumor Activity. J. Med. Chem. 2021, 64, 8391-8409. 

(5)  Shengjie Liu, Xinyu Zhou, Minglei Li, Wenfeng Zhao, Shuxi Zhou, Ke-guang Cheng, Qing-Long Xu, Caiping Chen, Xiaoan Wen, Hongbin Sun*, Haoliang Yuan*. Discovery of Ubiquitin Specific Protease 7 (USP7) Inhibitors with A Novel Scaffold Structure by Virtual Screening, Molecular Dynamics Simulation and Biological Evaluation. J. Chem. Inf. Model. 2020, 60, (6): 3255–3264.

(6)  Xiangying Zhang, Hongbin Sun, Xiaoan Wen*, Haoliang Yuan*. A Selectivity Study of FFAR4/FFAR1 Agonists by Molecular Modeling. J. Chem. Inf. Model. 2019, 59(10): 4467-4474. 

(7)  Haoliang Yuan#, Qiufeng Liu#, Li Zhang#, Shihe Hu, Tiantian Chen, Huifang Li, Yadong Chen, Yechun Xu*, Tao Lu*. Discovery, optimization and biological evaluation for novel c-Met kinase inhibitors. Eur. J. Med. Chem. 2018, 143, 491-502. 

(8)  Yongzhi Chang, Shuxi Zhou, Enqin Li, Wenfeng Zhao, Yanpeng Ji, Xiaoan Wen*, Hongbin Sun*, Haoliang Yuan*. Fragment-based discovery of novel pentacyclic triterpenoid derivatives as cholesteryl ester transfer protein inhibitors, Eur. J. Med. Chem. 2017, 126: 143-153. 

(9)  Haoliang Yuan, Jin Zhuang, Shihe Hu, Huifang Li, Jinxing Xu, Yaning Hu, Xiao Xiong, Yadong Chen* and Tao Lu*. Molecular Modeling of Exquisitely Selective c-Met Inhibitors through 3D-QSAR and Molecular Dynamics Simulations. J. Chem. Inf. Model. 2014, 54 (9), 2544–2554. 

(10)  Haoliang Yuan, Tao Lu, Ting Ran, Haichun Liu, Shuai Lu, Wenting Tai, Ying Leng, Weiwei Zhang, Jian Wang, Yadong Chen*. Novel strategy for three-dimensional fragment-based lead discovery. J. Chem. Inf. Model. 2011, 51 (4): 959-974.